Rigel Lands FDA Approval for Tavalisse
Rigel Pharmaceuticals secured FDA approval for its immune thrombocytopenia drug Tavalisse (fostamatinib disodium hexahydrate).
The drug, an SYK inhibitor, received the green light for adult patients with chronic immune thrombocytopenia who have not responded to previous treatment.
The drug works by inhibiting platelet destruction, the prime autoimmune cause of the disease. The disorder affects between 50,000 and 60,000 adults.
The company plans to launch Tavalisse in May.